A drug called Jemperli (dostarlimab ... consistent with the known safety profile of the agent." The press release also covers the various adverse reactions patients might experience.

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

Dostarlimab was approved as Jemperli for the treatment ... C-Reactive Protein. The 424-patient trial also indicated a well-tolerated safety profile for the experimental therapy, the company ...